Selected article for: "general population and social distancing"
Author: Nicholas Gray; Dominic Calleja; Alex Wimbush; Enrique Miralles-Dolz; Ander Gray; Marco De-Angelis; Elfride Derrer-Merk; Bright Uchenna Oparaji; Vladimir Stepanov; Louis Clearkin; Scott Ferson
Title: No test is better than a bad test"": Impact of diagnostic uncertainty in mass testing on the spread of Covid-19
  • Document date: 2020_4_22
    • ID: 2jwuzfan_46
    Snippet: . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Much of the discussion around antibody testing in the media has focused on the performance and number of these tests. Th.....
    Document: . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Much of the discussion around antibody testing in the media has focused on the performance and number of these tests. The efficacy of this strategy however is far more dependent on the prevalence of antibodies in the general population. Without wide-scale antibody screening it's impossible to know the prevalence of antibodies in the general population, so there is scientific value in such an endeavour. However, the prevalence is the dominant factor to determine how efficacious antibody screening would be for relaxing social distancing measures.

    Search related documents:
    Co phrase search for related documents
    • antibody prevalence and general population antibody prevalence: 1, 2, 3, 4, 5
    • antibody screening and cc NC ND International license: 1
    • antibody screening and general population: 1, 2, 3, 4
    • antibody screening and International license: 1
    • antibody screening and strategy efficacy: 1
    • antibody testing and general population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody testing and International license: 1, 2
    • antibody testing and scientific value: 1, 2
    • cc NC ND International license and distancing measure: 1, 2, 3, 4, 5
    • cc NC ND International license and general population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and number performance: 1
    • cc NC ND International license and social distancing measure: 1, 2, 3, 4, 5
    • distancing measure and general population: 1, 2, 3
    • distancing measure and International license: 1, 2, 3, 4, 5
    • distancing measure and social distancing measure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • dominant factor and International license: 1
    • general population and social distancing measure: 1, 2, 3
    • general population and strategy efficacy: 1, 2, 3